• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Verva Pharmaceuticals Limited - Product Pipeline Review - Q4 2010 Product Image

Verva Pharmaceuticals Limited - Product Pipeline Review - Q4 2010

  • ID: 1446142
  • November 2010
  • 28 pages
  • GlobalData

Verva Pharmaceuticals Limited – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Verva Pharmaceuticals Limited - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Verva Pharmaceuticals Limited - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Verva Pharmaceuticals Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, READ MORE >



List of Tables
List of Figures
Verva Pharmaceuticals Limited Snapshot
Verva Pharmaceuticals Limited Overview
Key Information
Key Facts
Verva Pharmaceuticals Limited – Research and Development Overview
Key Therapeutic Areas
Verva Pharmaceuticals Limited – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Verva Pharmaceuticals Limited – Pipeline Products Glance
Verva Pharmaceuticals Limited Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Verva Pharmaceuticals Limited–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Verva Pharmaceuticals Limited – Drug Profiles
VVP808
Product Description
Mechanism of Action
R&D Progress
IMPDH Inhibitors For Obesity
Product Description
Mechanism of Action
R&D Progress
Gene Expression Signature Platform
Product Description
Mechanism of Action
R&D Progress
VVP100X
Product Description
Mechanism of Action
R&D Progress
Verva Pharmaceuticals Limited – Pipeline Analysis
Verva Pharmaceuticals Limited – Pipeline Products by Therapeutic Class
Verva Pharmaceuticals Limited Pipeline Products By Target
Verva Pharmaceuticals Limited – Pipeline Products by Route of Administration
Verva Pharmaceuticals Limited – Pipeline Products by Molecule Type
Verva Pharmaceuticals Limited – Locations And Subsidiaries
Head Office
Recent Developments
Oct 27, 2008: Verva Scientific Collaborators Receive Australian Government Grant To Advance GES Diabetes Discovery Platform
Financial Deals Landscape
Verva Pharmaceuticals Limited, Deals Summary, 2004 to 2010
Verva Pharmaceuticals Limited Detailed Deal Summary
Venture Financing
Verva Pharmaceuticals Secures $2.1 Million In Series A Round Of Financing
Licensing Agreements
Verva Pharmaceuticals Enters Into Licensing Agreement With Isis Pharmaceuticals
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS